Notice of Proposed Sale · 144
Bruker Corporation
BRKRNASDAQEQUITYCurrent
Notice of Proposed Sale
Structured filing — 144
primary_doc.xml
Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.
Proposed-sale notice
- Issuer
- Bruker Corporation
- Issuer CIK
- 0001109354
- SEC file number
- 001-42828
- Phone
- 978-663-3660
- Person for whose account securities are to be sold
- MARK R MUNCH
- Relationships to issuer
- Officer
- Street
- 40 Manning Road
- City
- Billerica,
- State / country code
- MA
- Postal code
- 01821
Securities proposed for sale
| Security | Proposed units | Aggregate market value | Units outstanding | Approximate sale date | Exchange | Broker / market maker |
|---|---|---|---|---|---|---|
| Common | 2,000 | 120,500.00 | 152,225,624 | 07/15/2026 | NASDAQ | Morgan Stanley Smith Barney LLC Executive Financial Services |
Broker / market maker — proposed row 1, entry 1
- Name
- Morgan Stanley Smith Barney LLC Executive Financial Services
- Street
- 1 New York Plaza
- Street (continued)
- 8th Floor
- City
- New York
- State / country code
- NY
- Postal code
- 10004
Acquisition of securities to be sold
| Security | Acquired | Nature of acquisition | Acquired from | Amount acquired | Gift transaction | Payment date | Nature of payment |
|---|---|---|---|---|---|---|---|
| Common | 07/15/2026 | Stock Option Exercise | ISSUER | 2,000 | N | 07/15/2026 | Cash |
Sales reported in the preceding three months
| Seller | Security | Sale date | Amount sold | Gross proceeds |
|---|---|---|---|---|
| MARK R MUNCH | Common | 06/15/2026 | 2,000 | 109,520.00 |
| MARK R MUNCH | Common | 05/15/2026 | 2,000 | 87,800.00 |
Seller — prior-sale row 1, entry 1
- Name
- MARK R MUNCH
- Street
- 40 Manning Road
- City
- Billerica,
- State / country code
- MA
- Postal code
- 01821
Seller — prior-sale row 2, entry 1
- Name
- MARK R MUNCH
- Street
- 40 Manning Road
- City
- Billerica,
- State / country code
- MA
- Postal code
- 01821
Prior-sale reporting
- Nothing to report for the preceding three months
- N
Notice signature
- Notice date
- 07/15/2026
- Signed
- /s/ Mark Munch
- Plan adoption dates
- 09/12/2025
Company context
Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker’s high-performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in post-genomic life science molecular and cell biology research, in specialty diagnostics, in applied and biopharma applications, in microscopy and nanoanalysis, as well as in industrial and cleantech research, and next-gen semiconductor metrology in support of AI. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, clinical microbiology and molecular diagnostics, as well as in the semiconductor industry. For more information, please visit www.bruker.com.